110 reports of this reaction
1.6% of all MINERAL OIL reports
#10 most reported adverse reaction
PULMONARY EMBOLISM is the #10 most commonly reported adverse reaction for MINERAL OIL, manufactured by OCuSOFT LLC. There are 110 FDA adverse event reports linking MINERAL OIL to PULMONARY EMBOLISM. This represents approximately 1.6% of all 6,758 adverse event reports for this drug.
Patients taking MINERAL OIL who experience pulmonary embolism should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY EMBOLISM is a less commonly reported adverse event for MINERAL OIL, but still significant enough to appear in the safety profile.
In addition to pulmonary embolism, the following adverse reactions have been reported for MINERAL OIL:
The following drugs have also been linked to pulmonary embolism in FDA adverse event reports:
PULMONARY EMBOLISM has been reported as an adverse event in 110 FDA reports for MINERAL OIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY EMBOLISM accounts for approximately 1.6% of all adverse event reports for MINERAL OIL, making it a notable side effect.
If you experience pulmonary embolism while taking MINERAL OIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.